{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:42:51Z","timestamp":1770039771983,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejca.2021.11.026","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T19:54:54Z","timestamp":1640202894000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study"],"prefix":"10.1016","volume":"162","author":[{"given":"Giulia","family":"Baciarello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneel","family":"Mundle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Leitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Richarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Feyerabend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3782-7226","authenticated-orcid":false,"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.11.026_bib1","first-page":"980","article-title":"Visceral metastases in prostate cancer: an underestimated and understudied subgroup","volume":"28","author":"Bourlon","year":"2014","journal-title":"Oncology (Williston Park, NY)"},{"key":"10.1016\/j.ejca.2021.11.026_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2021.11.026_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.11.026_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.11.026_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.11.026_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.11.026_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.11.026_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.026_bib9","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.11.026_bib10","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.11.026_bib11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2021.11.026_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.026_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.026_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2016.06.033","article-title":"Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302","volume":"71","author":"de Bono","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2021.11.026_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/pcan.2013.41","article-title":"Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"17","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2021.11.026_bib16","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2217\/fon.15.158","article-title":"Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients","volume":"11","author":"Conteduca","year":"2015","journal-title":"Future Oncol (London, England)"},{"key":"10.1016\/j.ejca.2021.11.026_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/CAD.0000000000000703","article-title":"Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience","volume":"30","author":"Facchini","year":"2019","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejca.2021.11.026_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.026_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"European J Cancer"},{"key":"10.1016\/j.ejca.2021.11.026_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","article-title":"Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"103","author":"Feyerabend","year":"2018","journal-title":"European J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.026_bib21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.026_bib22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2021.11.026_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clgc.2020.06.001","article-title":"Treating de novo metastatic castration-sensitive prostate cancer with visceral metastases: an evolving issue","volume":"19","author":"Roviello","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2021.11.026_bib24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clgc.2017.02.007","article-title":"Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL trial","volume":"15","author":"Alumkal","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2021.11.026_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncr.30336","article-title":"Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and\/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial","volume":"123","author":"Loriot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.11.026_bib26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.11.026_bib27","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:24Z","timestamp":1760733264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"alternative-id":["S0959804921012284"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}